CoChat

Menopausal hormone therapy and breast cancer risk: Impact of different treatments. The European Prospective Investigation into Cancer and Nutrition

Open access
Bakken, Kjersti, Fournier, Agnès, Lund, Eiliv, Waaseth, Marit, Dumeaux, Vanessa, Clavel‐Chapelon, Françoise, Fabre, Alban, Hémon, Bertrand, Rinaldi, Sabina, Chajes, Véronique, Slimani, Nadia, Allen, Naomi E., Reeves, Gillian K., Bingham, Sheila, Khaw, Kay‐Tee, Olsen, Anja, Tjønneland, Anne, Rodriguez, Laudina, Sánchez, Maria‐José, Etxezarreta, Pilar Amiano, Ardanaz, Eva, Tormo, Maria‐José, Peeters, Petra H., van Gils, Carla H., Steffen, Annika, Schulz, Mandy, Chang‐Claude, Jenny, Kaaks, Rudolf, Tumino, Rosario, Gallo, Valentina, Norat, Teresa, Riboli, Elio, Panico, Salvatore, Masala, Giovanna, González, Carlos A., Berrino, Franco · 2011 · International Journal of Cancer
Cited by 142

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Menopausal hormone therapy (MHT) is characterized by use of different constituents, regimens and routes of administration. We investigated the association between the use of different types of MHT and breast cancer risk in the EPIC cohort study. The analysis is based on data from 133,744 postmenopausal women. Approximately 133,744 postmenopausal women contributed to this analysis. Information on MHT was derived from country‐specific self‐administered questionnaires with a single baseline assessment. Incident breast cancers were identified through population cancer registries or by active follow‐up (mean: 8.6 yr). Overall relative risks (RR) and 95% confidence interval (CI) were derived from country‐specific Cox proportional hazard models estimates. A total of 4312 primary breast cancers were diagnosed during 1,153,747 person‐years of follow‐up. Compared with MHT never users, breast cancer risk was higher among current users of estrogen only (RR: 1.42, 95% CI 1.23–1.64) and higher still among current users of combined MHT (RR: 1.77, 95% CI 1.40–2.24; p = 0.02 for combined vs. estrogen‐only). Continuous combined regimens conferred a 43% (95% CI: 19–72%) greater risk compared with sequential regimens. There was no significant difference between progesterone and testosterone derivatives in sequential regimens. There was no significant variation in risk linked to the estrogenic component of MHT, neither for oral vs. cutaneous administration nor for estradiol compounds vs. conjugated equine estrogens. Estrogen‐only and combined MHT uses were associated with increased breast cancer risk. Continuous combined preparations were associated with the highest risk. Further studies are needed to disentangle the effects of the regimen and the progestin component.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.25314

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 142

Metadata

Authors
Bakken, K., Fournier, A., Lund, E., Waaseth, M., Dumeaux, V., Clavel‐Chapelon, F., Fabre, A., Hémon, B., Rinaldi, S., Chajes, V., Slimani, N., Allen, N. E., Reeves, G. K., Bingham, S., Khaw, K., Olsen, A., Tjønneland, A., Rodriguez, L., Sánchez, M., Etxezarreta, P. A., Ardanaz, E., Tormo, M., Peeters, P. H., van Gils, C. H., Steffen, A., Schulz, M., Chang‐Claude, J., Kaaks, R., Tumino, R., Gallo, V., Norat, T., Riboli, E., Panico, S., Masala, G., González, C. A., & Berrino, F.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2010-10-27
Volume
128
Issue
1
Pages
144-156
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2000011119
Cited by
142
References
4
FWCI
9.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.